Acute Pain Drug Pipeline Analysis Report 2025
Description
According to the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), approximately 40 million adults (17.6%) people experience severe levels of pain in the United States. The treatment for acute pain includes drugs and therapies. Common drugs include anti-seizure drugs, shots, muscle relaxers, and opioids. Several clinical trials are developing acute pain therapeutics including analgesics. The FDA has recently granted VX-548 Breakthrough Therapy Designation for the treatment of moderate to severe acute pain.
Report Coverage
The Acute Pain Drug Pipeline Report by Expert Market Research gives comprehensive insights into acute pain drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute pain. The acute pain pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from acute pain.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing acute pain pipeline development activities are covered in the report.
Acute Pain Drug Pipeline Outlook
Acute pain comes on suddenly and is caused by something specific usually and it is sharp in quality. This pain usually doesn’t last longer than a period of six months. It may be related to soft-tissue injury also or sometimes a temporary illness. The pain from an injury develops into chronic pain if the injury doesn’t heal correctly. The causes of acute pain include surgery, broken bones, burns or cuts, labor, and childbirth among others. The symptoms of acute pain include burning, numbness, tingling, and weakness among others.
Acute pain therapeutic drugs include medications, massage therapy, physical therapy, and topical treatments among others. The medications include anti-seizure drugs, shots, muscle relaxers, and opioids. Anti-seizure drugs relieve numbness and tingling (if there is nerve damage). Sometimes doctors prescribe injecting a corticosteroid medicine in the injured areas to reduce inflammation. Muscle relaxers help loosen tight muscles and opioids are prescribed drugs to relieve severe acute pain. Several pharma companies and research institutes are developing acute pain emerging drugs to manage acute pain. For instance, analgesic trials are investigated for acute pain in the context of traumatic injury or surgical procedures. The increasing clinical trials and changing dynamics are impacting the acute pain clinical trial landscape significantly.
Acute Pain – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of acute pain drugs based on several segmentations including:
By Phase:
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s acute pain therapeutic assessment covers 50+ drug analyses based on drug classes:
EMR’s acute pain clinical assessment covers 50+ drug analyses based on the route of administration.
The acute pain report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for acute pain.
Acute Pain – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under acute pain pipeline analysis include oligonucleotide, peptide, and small molecule. Small molecules are used to develop acute pain treatment such as nociceptor-selective treatments. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute pain.
Acute Pain Clinical Trials Assessment – Competitive Dynamics
The EMR acute pain report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute pain clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and acute pain therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming acute pain drug candidates.
Drug: Etodolac
The trial is designed to compare the efficacy of the fixed-dose combination of etodolac and cyclobenzaprine in postoperative pain control. The trial is sponsored by Apsen Farmaceutica S.A. and is currently under phase III.
Drug: VX-548
The objective of the study is to assess the safety and efficacy of acute pain drug candidate VX-548 for treating acute pain after an abdominoplasty. The trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently under phase III.
Drug: VX-150
Vertex Pharmaceuticals Incorporated is developing the drug and is currently under phase II. The study is being conducted to assess the dose-response relationship and safety of VX-150 in treating acute pain.
Reasons To Buy This Report
The Acute Pain Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute pain pipeline insight.
Key Questions Answered in the Acute Pain – Pipeline Assessment Report
Global Postoperative Pain Therapeutics Market
United States Topical Pain Relief Market
Global Chronic Lower Back Pain Treatment Market
Report Coverage
The Acute Pain Drug Pipeline Report by Expert Market Research gives comprehensive insights into acute pain drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute pain. The acute pain pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from acute pain.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing acute pain pipeline development activities are covered in the report.
Acute Pain Drug Pipeline Outlook
Acute pain comes on suddenly and is caused by something specific usually and it is sharp in quality. This pain usually doesn’t last longer than a period of six months. It may be related to soft-tissue injury also or sometimes a temporary illness. The pain from an injury develops into chronic pain if the injury doesn’t heal correctly. The causes of acute pain include surgery, broken bones, burns or cuts, labor, and childbirth among others. The symptoms of acute pain include burning, numbness, tingling, and weakness among others.
Acute pain therapeutic drugs include medications, massage therapy, physical therapy, and topical treatments among others. The medications include anti-seizure drugs, shots, muscle relaxers, and opioids. Anti-seizure drugs relieve numbness and tingling (if there is nerve damage). Sometimes doctors prescribe injecting a corticosteroid medicine in the injured areas to reduce inflammation. Muscle relaxers help loosen tight muscles and opioids are prescribed drugs to relieve severe acute pain. Several pharma companies and research institutes are developing acute pain emerging drugs to manage acute pain. For instance, analgesic trials are investigated for acute pain in the context of traumatic injury or surgical procedures. The increasing clinical trials and changing dynamics are impacting the acute pain clinical trial landscape significantly.
Acute Pain – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of acute pain drugs based on several segmentations including:
By Phase:
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s acute pain therapeutic assessment covers 50+ drug analyses based on drug classes:
- Oligonucleotide
- Peptide
- Small Molecule
EMR’s acute pain clinical assessment covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The acute pain report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for acute pain.
Acute Pain – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under acute pain pipeline analysis include oligonucleotide, peptide, and small molecule. Small molecules are used to develop acute pain treatment such as nociceptor-selective treatments. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute pain.
Acute Pain Clinical Trials Assessment – Competitive Dynamics
The EMR acute pain report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute pain clinical trials:
- Centrexion Therapeutics
- Alaxia SAS
- Purdue Pharma, Canada
- Aponia Laboratories, Inc.
- Mundipharma SAS
- Apsen Farmaceutica S.A.
- Trevena Inc.
- Tris Pharma, Inc.
- Vertex Pharmaceuticals Incorporated
- Pharmbio Korea Co., Ltd.
- Unither Pharmaceuticals, France
- Sparian Biosciences, Inc
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and acute pain therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming acute pain drug candidates.
Drug: Etodolac
The trial is designed to compare the efficacy of the fixed-dose combination of etodolac and cyclobenzaprine in postoperative pain control. The trial is sponsored by Apsen Farmaceutica S.A. and is currently under phase III.
Drug: VX-548
The objective of the study is to assess the safety and efficacy of acute pain drug candidate VX-548 for treating acute pain after an abdominoplasty. The trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently under phase III.
Drug: VX-150
Vertex Pharmaceuticals Incorporated is developing the drug and is currently under phase II. The study is being conducted to assess the dose-response relationship and safety of VX-150 in treating acute pain.
Reasons To Buy This Report
The Acute Pain Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute pain pipeline insight.
Key Questions Answered in the Acute Pain – Pipeline Assessment Report
- What is the current landscape of acute pain disease pipeline drugs?
- Which companies/institutions are developing acute pain disease emerging drugs?
- How many phase II drugs are currently present in acute pain disease pipeline drugs?
- Which company is leading the acute pain disease pipeline development activities?
- What is the current acute pain disease therapeutic assessment?
- What are the opportunities and challenges present in the acute pain disease drug pipeline landscape?
- What is the efficacy and safety profile of acute pain disease pipeline drugs?
- Which companies/institutions are involved in acute pain disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in acute pain disease?
Global Postoperative Pain Therapeutics Market
United States Topical Pain Relief Market
Global Chronic Lower Back Pain Treatment Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Acute Pain
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Acute Pain
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Acute Pain: Epidemiology Snapshot
- 5.1 Acute Pain Incidence by Key Markets
- 5.2 Acute Pain– Patients Seeking Treatment in Key Markets
- 6 Acute Pain: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Acute Pain: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Acute Pain, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Acute Pain Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Acute Pain Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Methoxyflurane 3mL
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Methoxyflurane
- 10.2.3 Drug: Cebranopadol
- 10.2.4 Other Drugs
- 11 Acute Pain Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Morphine
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: VX-548
- 11.2.3 Other Drugs
- 12 Acute Pain Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: TRV130 1.5 mg
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: MNK-155
- 12.2.3 Other Drugs
- 13 Acute Pain Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug: MNK-155
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Acute Pain, Key Drug Pipeline Companies
- 14.1 Centrexion Therapeutics
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Alaxia SAS
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Purdue Pharma, Canada
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Aponia Laboratories, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Mundipharma SAS
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Apsen Farmaceutica S.A.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Trevena Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Tris Pharma, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Vertex Pharmaceuticals Incorporated
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Pharmbio Korea Co., Ltd.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Unither Pharmaceuticals, France
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Sparian Biosciences, Inc
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
